0001104659-23-075977.txt : 20230629 0001104659-23-075977.hdr.sgml : 20230629 20230629060034 ACCESSION NUMBER: 0001104659-23-075977 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230629 ITEM INFORMATION: Other Events FILED AS OF DATE: 20230629 DATE AS OF CHANGE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioXcel Therapeutics, Inc. CENTRAL INDEX KEY: 0001720893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821386754 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38410 FILM NUMBER: 231054117 BUSINESS ADDRESS: STREET 1: 555 LONG WHARF DRIVE CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 203-643-8060 MAIL ADDRESS: STREET 1: 555 LONG WHARF DRIVE CITY: NEW HAVEN STATE: CT ZIP: 06511 8-K 1 tm2320028d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 29, 2023

BioXcel Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38410		82-1386754
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

555 Long Wharf Drive

New Haven, CT 06511

(Address of principal executive offices, including Zip Code)

(475) 238-6837

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		BTAI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01

Other Information.

On June 29, 2023, BioXcel Therapeutics, Inc. (“BTAI” or the “Company”) provided the following updates:

TRANQUILITY II Phase 3 Trial

The Company has announced positive topline results for TRANQUILITY II, a Phase 3 trial of BXCL501, the Company’s proprietary, orally dissolving film formulation of dexmedetomidine under investigation for the acute treatment of Alzheimer’s disease-related agitation.

The Phase 3 trial met its primary efficacy endpoint with the 60 mcg dose; a statistically significant and clinically meaningful 7.5 point reduction from baseline in Positive and Negative Syndrome Scale-Excitatory Component (PEC) total score was observed at 2 hours versus 5.4 with placebo (p=0.0112). The 60 mcg dose also met the first key secondary endpoint of reducing agitation symptoms at 1 hour during the first episode of agitation (p=0.0185) but did not meet the other key secondary endpoint of change from baseline in PEC score at 30 minutes.

Efficacy for this dose was supported by a number of secondary measures, including CGI-I and ACES. Most patients (76%) responded to the first 60 mcg dose and were determined to be “Very Much” or “Much Improved” (CGI-I of 1 or 2) compared to 50% with placebo. The primary endpoint was not met for the 40 mcg dose, with a 5.7 point reduction from baseline in PEC score.

BXCL501 continued to show a PEC reduction over repeated dosing. A total of 443 episodes were dosed over the 12-week trial period, including 294 episodes occurring after the first treatment across all dose groups. Dosing with 60 mcg showed a reduction in PEC total score from pre-dose versus placebo at 1 hour (p=0.011) and 2 hours (p=0.0044) for all episodes of agitation.

BXCL501 was well tolerated, with a side effect profile substantially consistent with prior trials of BXCL501 and the current label for IGALMI™. The 60 mcg dose had previously been evaluated in different patient populations and in healthy volunteers. Data from TRANQUILITY II add to this safety database and show that the majority of safety events occurring within 24 hours of dosing in this population were mild or moderate in severity and consistent with the current IGALMI™ label. In addition, dosing for subsequent episodes did not result in a meaningful increase in the number of adverse events and no treatment-related serious adverse events were observed over the 12-week study period.

For all 443 episodes over the 12-week period, there were no syncope or falls related to trial drug. All falls except one with placebo were outside the 24-hour treatment window (5 falls in the 40 mcg arm, 7 falls in the 60 mcg arm, and 5 falls in the placebo arm).

The Company plans to develop a path to potential sNDA submission for the acute treatment of agitation associated with Alzheimer’s disease in the second half of 2023, subject to further discussions with the U.S. Food and Drug Administration (“FDA”).

TRANQUILITY II Topline Results

Efficacy Results at 2 Hours (Primary Endpoint)

 

BXCL501 60 mcg
n=50

BXCL501 40 mcg

n=48

Placebo
n=51

Reduction in PEC Total Score
from Baseline LSM (SE)

7.5 (0.6)

5.7 (0.6)

5.4 (0.6)

p-value (vs. placebo)

0.0112*

0.7648

*Statistical significance achieved at 0.025

Adverse Events of Special Interest Reported Within 24 Hours of First Dose**

Adverse Event

Severity

BXCL501 60 mcg
n=50 (%)

BXCL501 40 mcg
n=48 (%)

Placebo
n=51 (%)

Somnolence*

Mild

Moderate

8 (16.0)

1 (2.0)

6 (12.5)
2 (4.2)

2 (3.9)

0

Lethargy

Mild

Moderate

2 (4.0)

1 (2.0)

1 (2.1)

1 (2.1)

1 (2.0)

0

Hypotension

Mild

Moderate

7 (14.0)

1 (2.0)

4 (8.3)

0

2 (3.9)

0

Bradycardia

Mild

Moderate

3 (6.0)

1 (2.0)

0

1 (2.1)

0

0

Orthostatic
Hypotension

Mild

Moderate

2 (4.0)

2 (4.0)

2 (4.2)

1 (2.1)

1 (2.0)

0

*Verbatim; drowsy or feeling sleepy

** The adverse events of special interest (AESI) are defined as those related to mechanism of action of the drug. Those that are listed were observed within 24 hours after the first dose and occur with a frequency of at least 2% and greater than with placebo. Subjects are counted once at highest severity for each preferred term

Important Information Regarding TRANQUILITY II Phase 3 Clinical Trial

In December 2022, the U.S. Food and Drug Administration (“FDA”) conducted an inspection of one of the clinical trial sites in the Phase 3 TRANQUILITY II clinical trial, where the principal investigator enrolled approximately 40% of the subjects participating in the trial. At the conclusion of this inspection, the FDA issued an FDA Form 483 identifying three inspectional observations. These observations related to the principal investigator’s failure to adhere to the informed consent form approved by the Institutional Review Board for a limited number of subjects whose records the FDA reviewed, maintain adequate case histories for certain patients whose records the FDA reviewed, and adhere to the investigational plan in certain instances. For example, the FDA cited the principal investigator’s delay in informing the sponsor’s medical monitor or pharmacovigilance safety vendor of a serious adverse event (“SAE”) for one of the subjects, which report was made to the Company’s vendor outside of the 24 hour time period prescribed by the clinical trial protocol. The principal investigator for this clinical site responded to the FDA observations within the time period requested. The FDA inspection remains open, however, as the FDA has not issued an Establishment Inspection Report.

In May 2023, it came to the Company’s attention that this same principal investigator in the TRANQUILITY II clinical trial may have fabricated email correspondence purporting to demonstrate that the investigator timely submitted to the Company’s pharmacovigilance safety vendor a report of an SAE from a different subject than the one cited in the FDA Form 483, and purporting to show that the vendor had confirmed receipt. Upon receipt of this information, the Company promptly initiated an investigation and recently received confirmation that the principal investigator fabricated the email correspondence related to the timing of the reporting of this SAE to the Company’s pharmacovigilance vendor to make it appear as though this SAE had been timely reported to the pharmacovigilance vendor as required by the clinical trial protocol. The Company also confirmed that this SAE had been timely entered into the electronic data capture system, even though the SAE had not been separately reported to the Company’s pharmacovigilance safety vendor within the 24 hour timeframe required under the protocol.

In connection with this ongoing investigation, the Company was made aware that the fabricated email correspondence was provided to the FDA by the principal investigator’s employer during the on-site inspection in December 2022. After unblinding of the data, the Company determined that the SAE that was the subject of this fabricated correspondence between the principal investigator and the Company’s pharmacovigilance vendor occurred in a subject in the placebo arm. This principal investigator has not participated in any other clinical trial sponsored or conducted by the Company. Moreover, the study was designed such that trained study staff other than principal investigators were to conduct assessments of the primary efficacy measure.

The Company is currently in the process of conducting an investigation into protocol adherence and data integrity at the principal investigator’s trial site and is in the process of retaining an independent third party to audit the data collected at the site. The Company’s ongoing investigation and/or the planned independent audit may uncover new findings regarding the integrity of the trial data from this principal investigator’s site, the accuracy of safety or efficacy findings, or the usability of the data in connection with a marketing application. The Company plans to complete its investigation as soon as possible, although the Company can provide no assurance regarding the timing of the completion of its own investigation or the timing of the completion of the planned independent audit of the trial site. Further, the Company has notified the FDA of these findings and the steps it intends to take to validate the integrity of the data generated by this investigator for the TRANQUILITY II trial.

In connection with the foregoing, the Company is providing the below supplemental risk factor:

Developments relating to the Company’s TRANQUILITY II Phase 3 trial may impact the timing of the Company’s development plans for, and prospects for regulatory approval of, BXCL501 for the acute treatment of agitation associated with dementia in patients with probable Alzheimer’s disease.

The timing of the Company’s marketing application and prospects for regulatory approval of BXCL501 for the acute treatment of agitation associated with dementia in patients with probable Alzheimer’s disease may be adversely impacted by these developments. For example, even if the Company’s investigation and the independent audit conclude that data from the TRANQUILITY II trial have not been affected or compromised by the principal investigator’s actions or other deficiencies at the trial site, the FDA may not accept or agree with the Company’s conclusions or analyses, or may interpret or weigh their importance differently. Further, if the Company or the FDA determines that there are issues with data integrity and/or compliance with good clinical practice requirements at the trial site, the Company may be unable to use some or all of the subject data generated at this clinical site to support a marketing application. If all or a substantial portion of such data were discarded, the TRANQUILITY II trial may no longer be adequately powered for statistical significance and the Company may need to conduct a new clinical trial. If the Company conducts a new Phase 3 trial, such trial may have different safety or efficacy results from the topline data the Company is announcing today. Topline data from the TRANQUILITY II trial, including results from subjects at this principal investigator’s site, may not be predictive of the results in any new trial. Further, any investigation, disqualification or debarment of, or proceeding or action against the principal investigator, or any investigation, proceeding or action against the Company, could further delay development and approval of BXCL501 for this indication, and otherwise have a material adverse effect on the Company, its financial condition, results of operations and prospects.

Forward-Looking Statements

This Current Report on Form 8-K (“Form 8-K”) includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this Form 8-K other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's expected timing of, trial design and data results from, future clinical trials and future regulatory approvals of BXCL501, in particular for treatment of dementia, potential safety and tolerability features of BXCL501, the potential addressable market for BXCL501 and the potential benefits from treatment with BXCL501. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its ability to receive regulatory approval for its product candidates and the possibility that the FDA does not conclude that its product candidates satisfy the regulatory requirements for approval; dependence on third-party clinical investigators who may not comply with good clinical practice or other regulatory requirements; the outcomes of its internal and third-party investigations into one of the principal investigators on the TRANQUILITY II trial; its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502 and BXCL701 and other product candidates; its lack of experience in marketing and selling drug products; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 29, 2023		BIOXCEL THERAPEUTICS, INC.

		/s/ Richard Steinhart
	By:	Richard Steinhart
	Title:	Chief Financial Officer

EX-101.SCH 2 btai-20230629.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 btai-20230629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 btai-20230629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 29, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 29, 2023
Entity File Number	001-38410
Entity Registrant Name	BioXcel Therapeutics, Inc.
Entity Central Index Key	0001720893
Entity Tax Identification Number	82-1386754
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	555 Long Wharf Drive
Entity Address, City or Town	New Haven
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06511
City Area Code	475
Local Phone Number	238-6837
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	BTAI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

XML 6 tm2320028d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001720893 2023-06-29 2023-06-29 iso4217:USD shares iso4217:USD shares 0001720893 false 8-K 2023-06-29 BioXcel Therapeutics, Inc. DE 001-38410 82-1386754 555 Long Wharf Drive New Haven CT 06511 475 238-6837 false false false false Common Stock, par value $0.001 BTAI NASDAQ true true EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioxceltherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2320028d1_8k.htm btai-20230629.xsd btai-20230629_lab.xml btai-20230629_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2320028d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2320028d1_8k.htm" ] }, "labelLink": { "local": [ "btai-20230629_lab.xml" ] }, "presentationLink": { "local": [ "btai-20230629_pre.xml" ] }, "schema": { "local": [ "btai-20230629.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BTAI", "nsuri": "http://bioxceltherapeutics.com/20230629", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2320028d1_8k.htm", "contextRef": "From2023-06-29to2023-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioxceltherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2320028d1_8k.htm", "contextRef": "From2023-06-29to2023-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioxceltherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001104659-23-075977-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-075977-xbrl.zip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end